Skip to content
Company Analysis

Gilead Sciences, Inc. GILD

A comprehensive view of key metrics, scores, and financial health for Gilead Sciences, Inc.

Overview of Gilead Sciences, Inc.

GILD NMS
Healthcare Drug Manufacturers - General Framework: Pharma / Mature Biotech Mega Cap
Gilead Sciences, Inc. (GILD), is a Mega Cap company, in the Drug Manufacturers - General industry, last closed at $170.33, about 65.4% overvalued vs fair value, +38.0% 1Y return, ranked 996/1145 in sector.
Metrics P/E 18.1× Rev Growth 2.4% ROE 40.5% Gross Margin 78.8% Div Yield 2.63%
USD 170.33
-0.21%
(Delayed)
• Vol 90d: 28.3%
52-Week Range
Market Cap
$211.27B
Enterprise Value
$234.25B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Fair
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Good
Valuation
Fair
Completeness: 100%
Confidence: 97%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.gilead.com
HQ Foster City, CA
Employees 17,000
Fiscal year Dec 31

Next Events

Dividend Dec 15

Fair Value Snapshot

Bear Base Bull
$54
$59
$64
Current: $170.33 -65% vs base

Engine Room Money Flow™

Mega Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$29.4B
2.4%%
Gross Profit
$23.2B
3.1%%
R&D Expense
$5.8B
-1.8%%
Operating Income (EBIT)
$10.8B
549.1%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
92.6%
Good

Good cash conversion

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$5.9B
62.7% of FCF

Where It Leaks

Cash Flow Health some concerns
Moderate efficiency issues detected. Review active leaks below for improvement areas.
2
Active Leaks
1/2
Improving
1
High Impact
0
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Gilead Sciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
68
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.83), suggesting sticky customer base.
  • Cash Generation Consistent Cash generation is consistent (score 0.97), indicating reliable business model.

Key risks

  • Volatile Margins Suggest Cyclicality Margin volatility is high (stability score 0.22), suggesting cyclical exposure or competitive pressure.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
54
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

vs Industry Peers 100% Coverage
Trade-Off Triangle Visualization A ternary plot showing GILD's balance between Growth (30.8%), Profitability (44.5%), and Safety (24.7%). Growth 31% Safety 25% Profitability 44%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

63th percentile vs peers
63
Key Signals
EPS Growth YoY 16.73 95p Rev Growth YoY 2.4% 45p Revenue CAGR 3Y 2.6% 46p EPS CAGR 3Y 23.1% 75p TSR 36.4% 72p
Strengths
  • EPS Growth YoY in top 20% of peers (16.73, 95th percentile)
  • Interest Coverage Ratio in top 20% of peers (10.57, 84th percentile)
  • Superior capital returns - 3 return metrics above peer median
  • Growth above peer median with strong metric coverage (100%)
Risks

No significant risks identified for this axis.

Profitability

91th percentile vs peers
91
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

50th percentile vs peers
51
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Gilead Sciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$58.91
- - -
-65.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000